A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease

Condition:   Crohn's Disease Intervention:   Drug: Mirikizumab Sponsor:   Eli Lilly and Company Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials

Related Links:

Condition:   Crohn's Disease (CD) Intervention:   Other: Time Restricted Feeding Sponsors:   Weill Medical College of Cornell University;   The Kenneth Rainin Foundation Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Crohn Disease Intervention:   Drug: Infliximab Sponsor:   Second Affiliated Hospital of Wenzhou Medical University Completed
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
CONCLUSIONS: our results support ABP 501 as an effective and well-tolerated drug, with a good interchangeability with its originator for the treatment of Crohn's disease. PMID: 32054272 [PubMed - as supplied by publisher]
Source: Revista Espanola de Enfermedades Digestivas - Category: Gastroenterology Tags: Rev Esp Enferm Dig Source Type: research
Conclusion: Two-thirds of the patients demonstrated stable clinical benefit from maintenance IFX. The results show steroid-sparing efficacy as well as improved quality of life and reduced need for surgery. PMID: 32052663 [PubMed - as supplied by publisher]
Source: Scandinavian Journal of Gastroenterology - Category: Gastroenterology Tags: Scand J Gastroenterol Source Type: research
Recent evidence points to a plausible role of diet and the microbiome in the pathogenesis of both Crohn ’s disease (CD) and Ulcerative Colitis (UC). Dietary therapies based on exclusion of table foods and replacement with nutritional formulas and/or a combination of nutritional formulas and specific table foods may induce remission in CD. In UC, specific dietary components have also been associated with flare of disease. While evidence of varying quality has identified potential harmful or beneficial dietary components, physicians and patients at the present time do not have guidance as to which foods are safe, may b...
Source: Clinical Gastroenterology and Hepatology - Category: Gastroenterology Authors: Source Type: research
We reported the event rates for the number of patients hospitalized, in a follow-up survey of 20,987 patient-years, and for the patients who underwent surgery in a follow-up of 5061 patient-years, with ORs of 0.233 with 95%CI 0.227-0.239, and 0.124 with 95%CI 0.114-0.135 (P
Source: The Israel Medical Association Journal - Category: General Medicine Tags: Isr Med Assoc J Source Type: research
Condition:   Diagnosis of Cronh's Disease Intervention:   Procedure: Extensive mesentery resection Sponsor:   Jewish General Hospital Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Crohn Disease;   Recurrence;   Crohn's Ileocolitis Intervention:   Procedure: Extensive mesentery resection Sponsors:   Jewish General Hospital;   Montreal General Hospital Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Diagnosis of Cronh's Disease Intervention:   Procedure: Extensive mesentery resection Sponsor:   Jewish General Hospital Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Crohn Disease Intervention:   Drug: Interleukin-2 (aldesleukin). Sponsor:   Boston Children’s Hospital Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Crohn's Disease | Inflammatory Bowel Disease | Research | Study